Company news

Kala Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 7, 2023

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 2, 2023

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

December 26, 2022

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

November 27, 2022

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

November 27, 2022

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 7, 2022

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

October 31, 2022

Kala Pharmaceuticals Announces Reverse Stock Split

October 19, 2022

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

August 18, 2022

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

August 17, 2022

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022

Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

August 7, 2022

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

August 3, 2022

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

July 10, 2022

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

June 1, 2022

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 22, 2022

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 15, 2022

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 8, 2022

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

May 2, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

April 30, 2022

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

April 3, 2022

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 28, 2022

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

March 22, 2022

Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare

March 7, 2022

Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 17, 2021

Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 14, 2021

Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call

November 14, 2021

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

November 14, 2021

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in November 2021

November 10, 2021

Kala Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call

November 7, 2021

Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors

October 17, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

September 6, 2021

Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 4, 2021

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in August

August 3, 2021

Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call

July 28, 2021

Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx

June 2, 2021

Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference

May 26, 2021

Kala Pharmaceuticals to Present at BofA Securities 2021 Healthcare Conference

May 5, 2021

Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 4, 2021

Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call

April 27, 2021

Kala Pharmaceuticals Announces Preferred Position for EYSUVIS™ on Cigna

March 15, 2021

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

February 24, 2021

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

February 17, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

February 15, 2021

Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

January 6, 2021

Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease

November 15, 2020

Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 4, 2020

Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease

October 26, 2020

Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 5, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.